High-Value Federal Grants ($5M+) — August 09, 2026

SIGA's firm-fixed-price contract with HHS/BARDA for smallpox antiviral development provides multi-year revenue visibility through 2029, with $447.2M already outlayed, indicating strong government commitment and stable cash flow.

The time-and-materials pricing structure and short 6-month base period for legal services create high cost uncertainty and limited forward visibility, with potential total value of $244M if options are exercised.

The one-year firm-fixed-price delivery order for medical disability exams in the Southeast region is nearly fully executed ($196.6M outlayed), providing completed revenue but limited growth visibility for Leidos Holdings.

SIGA TECHNOLOGIES faces cost overrun risk on its $626.5M firm-fixed-price contract if development costs exceed estimates, potentially compressing margins.

OUR RESCUE's $158.1M time-and-materials contract with HHS carries high pricing risk due to labor cost variability and a short 6-month base period, with potential for cost overruns.

HHS accounts for two of three contracts totaling $784.6M (79% of aggregate value), creating agency concentration risk for investors tracking these awards.

SIGA TECHNOLOGIES' $626.5M HHS contract provides a stable multi-year revenue stream through 2029, with potential for follow-on BARDA contracts in antiviral development as biodefense priorities persist.

Leidos Holdings (via QTC Medical Services) could capture follow-on VA medical disability examination contracts in other regions, given the $209.2M award's full-and-open competition and successful execution.

OUR RESCUE's $158.1M non-competed HHS contract suggests specialized legal capabilities, potentially leading to option exercises worth up to $244M total if HHS continues to rely on sole-source awards.

The $626.5M SIGA TECHNOLOGIES contract underscores sustained government investment in biodefense, with BARDA's commitment to smallpox antiviral development through 2029.

The $209.2M QTC Medical Services contract reflects ongoing VA reliance on private medical disability exams, but full-and-open competition limits moats for incumbents.

OUR RESCUE's $158.1M sole-source HHS award for legal services highlights agency urgency but lacks competitive transparency, typical of bridge contracts.

{"entity" => "SIGA TECHNOLOGIES", "reason" => "Long-term $626.5M HHS contract with execution risk on fixed-price terms", "trigger" => "Quarterly earnings reports for cost performance; contract modifications or option exercises"}

{"entity" => "OUR RESCUE", "reason" => "Non-competed $158.1M HHS contract with high pricing risk and short base period", "trigger" => "Option exercise decisions by HHS before February 2027; any protests or re-solicitations"}

{"entity" => "Leidos Holdings", "reason" => "Completed $209.2M VA contract with potential for follow-on awards", "trigger" => "VA re-compete announcements for medical disability examinations in other regions"}